Validation and refinement of chronic lung allograft dysfunction phenotypes in bilateral and single lung recipients

Annals of the American Thoracic Society

Volumn 13, Issue 5, 2016, Pages 627-635

  Hovanessian, Ariss Der ^a   Todd, Jamie L ^b   Zhang, Alice ^a   Li, Ning ^a   Mayalall, Aradhna ^a   Copeland, C Ashley Finlen ^b   Shino, Michael ^a   Pavlisko, Elizabeth N ^c   Wallace, W Dean ^d   Gregson, Aric ^e   Ross, David J ^a   Saggar, Rajan ^a   Lynch, Joseph P ^a   Belperio, John ^a   Snyder, Laurie D ^b   Palmer, Scott M ^b   Weigt, S Sam ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Section of Infectious Diseases   (United States)

Author keywords

Bronchiolitis obliterans; Graft rejection; Lung transplantation; Spirometry

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; FORCED VITAL CAPACITY; GRAFT RECIPIENT; HUMAN; LUNG GRAFT REJECTION; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); PHENOTYPE; PLEURAL FIBROSIS; PROGNOSIS; RETROSPECTIVE STUDY; SPIROMETRY; VALIDATION STUDY; AGED; ALLOGRAFT; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIMARY GRAFT DYSFUNCTION; RISK FACTOR; SURGERY; SURVIVAL ANALYSIS; UNITED STATES; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ALLOGRAFTS; BRONCHIOLITIS OBLITERANS; FEMALE; HUMANS; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; PRIMARY GRAFT DYSFUNCTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; VITAL CAPACITY;

EID: 84989233267     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201510-719OC     Document Type: Article

References (23)

1. Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Lund LH, Rahmel AO, et al.; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report-2013; focus theme: Age. J Heart Lung Transplant 2013;32: 965-978.
2. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002;21: 297-310.
3. Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J, Mauer J, Paradis I, Patterson GA, Smith C, et al.; International Society for Heart and Lung Transplantation. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12:713-716.
4. Ofek E, Sato M, Saito T, Wagnetz U, Roberts HC, Chaparro C, Waddell TK, Singer LG, Hutcheon MA, Keshavjee S, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol 2013;26:350-356.
5. Pakhale SS, Hadjiliadis D, Howell DN, Palmer SM, Gutierrez C, Waddell TK, Chaparro C, Davis RD, Keshavjee S, Hutcheon MA, et al. Upper lobe fibrosis: A novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant 2005; 24:1260-1268.
6. Paraskeva M, McLean C, Ellis S, Bailey M, Williams T, Levvey B, Snell GI, Westall GP. Acute fibrinoid organizing pneumonia after lung transplantation. Am J Respir Crit Care Med 2013;187:1360-1368.
7. Woodrow JP, Shlobin OA, Barnett SD, Burton N, Nathan SD. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant 2010;29:1159-1164.
8. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 2014;33:127-133.
9. Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, Wagnetz D, Chaparro C, Singer LG, Hutcheon MA, et al. Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011;30:735-742.
10. Todd JL, Jain R, Pavlisko EN, Finlen Copeland CA, Reynolds JM, Snyder LD, Palmer SM. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. Am J Respir Crit Care Med 2014;189:159-166.
11. DerHovanessian A, Li N, Shino M, Sayah DM, Gregson AL, Lynch III JP, Saggar R, Ardehali A, Ross DJ, Elashoff RM, et al. Defining clinically relevant CLAD phenotypes in bilateral and single lung transplant recipients [abstract]. J Heart Lung Transplant 2014;33:S42.
12. Weigt SS, Copeland CA, Derhovanessian A, Shino MY, Davis WA, Snyder LD, Gregson AL, Saggar R, Lynch JP III, Ross DJ, et al. Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: A two-center validation study. Am J Transplant 2013;13:919-927.
13. Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Husain AN, Hruban RH, Marchevsky A, Ohori NP, Ritter J, Stewart S, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996;15:1-15.
14. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005;24:1454-1459.
15. Finlen Copeland CA, Snyder LD, Zaas DW, Turbyfill WJ, Davis WA, Palmer SM. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 2010; 182:784-789.
16. Snyder LD, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, Zaas DW, Palmer SM. Implications for human leukocyte antigen antibodies after lung transplantation: A 10-year experience in 441 patients. Chest 2013;144:226-233.
17. Willner DL, Hugenholtz P, Yerkovich ST, Tan ME, Daly JN, Lachner N, Hopkins PM, Chambers DC. Reestablishment of recipientassociated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2013; 187:640-647.
18. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296-307.
19. Popli R, Sahaf B, Nakasone H, Lee JY, Miklos DB. Clinical impact of H-Y alloimmunity. Immunol Res 2014;58:249-258.
20. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008;177: 1033-1040.
21. Witt CA, Gaut JP, Yusen RD, Byers DE, Iuppa JA, Bennett Bain K, Alexander Patterson G, Mohanakumar T, Trulock EP, Hachem RR. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2013;32:1034-1040.
22. Sato M, Hwang DM, Ohmori-Matsuda K, Chaparro C, Waddell TK, Singer LG, Hutcheon MA, Keshavjee S. Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation. J Heart Lung Transplant 2012;31:354-363.
23. Shino MY, Weigt SS, Li N, Palchevskiy V, Derhovanessian A, Saggar R, Sayah DM, Gregson AL, Fishbein MC, Ardehali A, et al. CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction. Am J Respir Crit Care Med 2013;188:1117-1125.